Citations

Clear

273 citation(s) found for "Simone, N De".

COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Parodis, Ioannis , Sen, Parikshit , Ravichandran, Naveen , Day, Jessica , Joshi, Mrudula , Jagtap, Kshitij , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Gupta, Vikas , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danieli, Maria Giovanna , Giollo, Alessandro, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Giollo, Alessandro , Gupta, Latika , Agarwal, Vishwesh , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Day, Jessica , Parodis, Ioannis , Nune, Arvind , Naveen, R , Agarwal, Vikas , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Andreoli, Laura , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Agarwal, Vishwesh , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Makol, Ashima , Barman, Bhupen , Torre, Ignacio García‐De La , Goo, Phonpen Akawatcharangura , Chen, Yi‐Ming , Halabi, Hussein , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Pilania, Rakesh Kumar , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Alunno, Alessia , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | July 25, 2023 | Volume: 63 | Issue: 5 | Pages: 1341-1351

10.1093/rheumatology/kead382 | PMID 37505460 Get It

Abstract Objectives We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P < 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
ENIGMA CHEK2 gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Stolařová, Lenka , Kleiblová, Petra , Šťastná, Barbora , Janatová, Markéta , Soukupová, Jana , Achatz, Maria Isabel , Ambrosone, Christine B. , Apostolou, Paraskevi , Arun, Banu , Auer, Paul L. , Bertelsen, Birgitte , Japan, Biobank, Kamatani, Yoichiro, Morisaki, Takayuki , Nagai, Akiko , Muto, Kaori , Murakami, Yoshinori , Furukawa, Yoichi , Yamanashi, Yuji , Nakamura, Yusuke , Momozawa, Yukihide , Ohnishi, Yozo, Kubo, Michiaki , Higashiue, Shinichi , Kobayashi, Shuzo , Minami, Shiro, Yamaguhci, Hiroki, Arai, Hajime , Yamaji, Ken , Asai, Satoshi , Fujioka, Tomoaki, Obara, Wataru , Mori, Seijiro, Murayama, Shigeo , Miki, Yoshio , Masumoto, Akihide, Yamada, Akira , Nishizawa, Yasuko, Higashiyama, Masahiko, Kutsumi, Hiromu, Koretsune, Yukihiro , Blok, Marinus J. , Brunet, Joan , Calvello, Mariarosaria , Chen, Fei , Cortesi, Laura , Crujeiras-González, Ana , Černá, Marta , Hovhannisyan, Milena, Jelínková, Sandra , Nehasil, Petr , Macháčková, Eva , Krutilkova, Vera, Tavandzis, Spiros , Cerna, Leona, Chvojka, Štěpán, Koudová, Monika , Puchmajerová, Alena, Novotný, Jan , Veselá, Kamila , Hrušková, Lucie , Michalovska, Renata, Schwetzova, Denisa, Vlčková, Zdeňka, Černá, Monika, Hejnalová, Markéta, Jedlickova, Nikol, Šubrt, Ivan , Zavoral, Tomas, Kosařová, Marcela, Vacínová, Gabriela, Janíková, Mária , Kratochvílová, Romana , Curtisová, Václava , Vrtěl, Radek , Scheinost, Ondřej, Duskova, Petra, Putter, Robin De , Efremidis, Anna , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Fuentes-Ríos, Olivia , Gómez, E. , Haiman, Christopher A. , Hansen, Thomas van Overeem , Hodge, James M. , Huang, Hongyan , Ishak, Nur Diana Binte , Iwasaki, Yusuke , Konstantopoulou, Irene , Li, Na , Lindström, Sara , Lori, Adriana , Martinez, Elana, Martins, Alexandra , McInerny, Simone , Montagna, Marco , Mori, Luigi , Nathanson, Katherine L. , Patel, Alpa V. , Poppe, Bruce , Rosseel, Toon , Ruddy, Kathryn J. , Santos, Elizabeth Santana Dos , Vachon, Celine M. , Volk, Alexander E. , Weber‐Lassalle, Nana , Weitzel, Jeffrey N. , Yadav, Siddhartha , Zethoven, Magnus, Zhang, Ze Wen, Vega, Ana , Rossing, Maria , Valle, Jesús Del , Nicolo, Arcangela De , Hahnen, Eric , Ngeow, Joanne , Kleibl, Zdeněk , Chen, Chen , Zemankova, Petra , Stastna, Barbora , Janatova, Marketa , Soukupova, Jana , Achatz, M I , Ambrosone, Christine B , Apostolou, Paraskevi , Arun, Banu , Auer, Paul , Barnard, Mollie , Bertelsen, Birgitte , Blok, Marinus J , Boddicker, Nicholas J , Brunet, Joan , Burnside, Elizabeth S , Calvello, Mariarosaria , Campbell, Ian G , Chan, Sock Hoai , Chen, Fei , Chiang, Jian Bang , Coppa, Anna , Cortesi, Laura , Crujeiras-González, Ana , De Leeneer, Kim , de Putter, Robin , DePersia, Allison , Devereux, Lisa , Domchek, Susan M , Efremidis, Anna , Engel, Christoph , Ernst, Corinna , Evans, D Gareth , Feliubadaló, Lidia , Fostira, Florentia , Fuentes-Ríos, Olivia , Gómez-García, Encarna B , González, Sara , Haiman, Christopher A , Hansen, Thomas van Overeem , Hauke, Jan , Hodge, James M , Hu, Chunling , Huang, Hongyan , Ishak, Nur Diana Binte , Iwasaki, Yusuke , Konstantopoulou, Irene , Kraft, Peter , Lacey, James V. , Lazaro, Conxi , Li, Na , Lim, Weng Khong , Lindstrom, Sara , Lori, Adriana , Martı́nez, Marı́a Elena , Martins, Alexandra , Matsuda, Koichi , Matullo, Giuseppe , McInerny, Simone , Michailidou, Kyriaki , Montagna, Marco , Monteiro, Alvaro N , Mori, Luigi , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Olson, Janet E , Palmer, Julie R , Pasini, Barbara , Patel, Alpa V , Piane, Maria , Poppe, Bruce , Radice, Paolo , Renieri, Alessandra , Resta, Nicoletta , Richardson, Marcy E , Rosseel, Toon , Ruddy, Kathryn J , Santamariña, Marta , Dos Santos, Elizabeth Santana , Teras, Lauren R , Toland, Amanda Ewart , Trentham-Dietz, Amy , Vachon, Celine M. , Volk, Alexander E , Weber-Lassalle, Nana , Weitzel, Jeffrey N , Wiesmuller, Lisa , Winham, Stacey J , Yadav, Siddhartha , Yannoukakos, Drakoulis , Yao, Song , Zampiga, Valentina , Zethoven, Magnus , Zhang, Ze Wen , Zima, Tomas , Spurdle, Amanda B , Vega, Ana , Rossing, Maria , Del Valle, Jesús , De Nicolo, Arcangela , Hahnen, Eric , Claes, Kathleen B M , Ngeow, Joanne , Momozawa, Yukihide , James, Paul , Couch, Fergus J. , Macurek, Libor , Kleibl, Zdenek , Chen, C , Japan, Biobank, Kamatani, Yoichiro, Mushiroda, Taisei , Tanaka, Toshihiro , Yamaguhci, Hiroki, Okazaki, Yasushi , Takahashi, Yasuo , Nagayama, Satoshi , Yoshiyama, Takashi , Boddicker, Nicholas , Burnside, Elizabeth S. , Campbell, Ian , Borecká, Marianna , Foretová, Lenka , Havránek, Ondřej , Vočka, Michal , Michalovska, Renata, Schwetzova, Denisa, Jedlickova, Nikol, Zavoral, Tomáš, Duskova, Petra, Stránecký, Viktor , Leeneer, Kim De , Domchek, Susan M. , González, Sara , Hauke, Jan , Hu, Chunling , Kraft, Peter , Lázaro, Conxi , Matullo, Giuseppe , Michailidou, Kyriaki , Monteiro, Álvaro N.A. , Nevanlinna, Heli , Olson, Janet E. , Palmer, Julie R. , Pasini, Barbara , Radice, Paolo , Renieri, Alessandra , Santamariña, Marta , Teras, Lauren R. , Trentham‐Dietz, Amy , Wiesmüller, Lisa , Winham, Stacey J. , Yannoukakos, Drakoulis , Yao, Song , Zampiga, Valentina , Spurdle, Amanda B. , Claes, Kathleen , James, Paul A. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | July 14, 2023 | Volume: 29 | Issue: 16 | Pages: 3037-3050

10.1158/1078-0432.ccr-23-0212 | PMID 37449874 Get It

Abstract Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense CHEK2 variants of uncertain significance (VUS) have been identified, hampering the clinical utility of germline genetic testing (GGT). Experimental Design: We collected 460 CHEK2 missense VUS identified by the ENIGMA consortium in 15 countries. Their functional characterization was performed using CHEK2-complementation assays quantifying KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1–CHEK2-knockout cells. Concordant results in both functional assays were used to categorize CHEK2 VUS from 12 ENIGMA case–control datasets, including 73,048 female patients with breast cancer and 88,658 ethnicity-matched controls. Results: A total of 430/460 VUS were successfully analyzed, of which 340 (79.1%) were concordant in both functional assays and categorized as functionally impaired (N = 102), functionally intermediate (N = 12), or functionally wild-type (WT)–like (N = 226). We then examined their association with breast cancer risk in the case–control analysis. The OR and 95% CI (confidence intervals) for carriers of functionally impaired, intermediate, and WT-like variants were 2.83 (95% CI, 2.35–3.41), 1.57 (95% CI, 1.41–1.75), and 1.19 (95% CI, 1.08–1.31), respectively. The meta-analysis of population-specific datasets showed similar results. Conclusions: We determined the functional consequences for the majority of CHEK2 missense VUS found in patients with breast cancer (3,660/4,436; 82.5%). Carriers of functionally impaired missense variants accounted for 0.5% of patients with breast cancer and were associated with a moderate risk similar to that of truncating CHEK2 variants. In contrast, 2.2% of all patients with breast cancer carried functionally wild-type/intermediate missense variants with no clinically relevant breast cancer risk in heterozygous carriers.
Open-Spaced Ridged Hydrogel Scaffolds Containing TiO2-Self-Assembled Monolayer of Phosphonates Promote Regeneration and Recovery Following Spinal Cord Injury
Siddiqui, Ahad M. , Thiele, Frederic, Stewart, Rachel , Rangnick, Simone, Weiss, Georgina J., Chen, Bingkun K. , Silvernail, Jodi L., Strickland, Tammy , Nesbitt, Jarred J., Lim, Kelly, Schwarzbauer, Jean E. , Yaszemski, Michael J. , Windebank, Anthony J. , Madigan, Nicolas N. , Stewart, Rachel N , Madigan, Nicolas N , Schwartz, Jeffrey

Mayo Clinic

International Journal of Molecular Sciences | June 16, 2023 | Volume: 24 | Issue: 12 | Pages: 10250

10.3390/ijms241210250 | PMID 37373396 Get It

The spinal cord has a poor ability to regenerate after an injury, which may be due to cell loss, cyst formation, inflammation, and scarring. A promising approach to treating a spinal cord injury (SCI) is the use of biomaterials. We have developed a novel hydrogel scaffold fabricated from oligo(poly(ethylene glycol) fumarate) (OPF) as a 0.08 mm thick sheet containing polymer ridges and a cell-attractive surface on the other side. When the cells are cultured on OPF via chemical patterning, the cells attach, align, and deposit ECM along the direction of the pattern. Animals implanted with the rolled scaffold sheets had greater hindlimb recovery compared to that of the multichannel scaffold control, which is likely due to the greater number of axons growing across it. The immune cell number (microglia or hemopoietic cells: 50–120 cells/mm2 in all conditions), scarring (5–10% in all conditions), and ECM deposits (Laminin or Fibronectin: approximately 10–20% in all conditions) were equal in all conditions. Overall, the results suggest that the scaffold sheets promote axon outgrowth that can be guided across the scaffold, thereby promoting hindlimb recovery. This study provides a hydrogel scaffold construct that can be used in vitro for cell characterization or in vivo for future neuroprosthetics, devices, or cell and ECM delivery.
Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study
Ziadé, Nelly , Aoude, Marc, Hmamouchi, Ihsane , Naveen, R, Sen, Parikshit , Joshi, Mrudula , Agarwal, Vishwesh , Kardeş, Sinan , Day, Jessica , Milchert, Marcin , Gheita, Tamer A. , Salim, Babur , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Kuwana, Masataka , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, the COVAD Study, Singh, Yogesh Preet , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Pauling, John D , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Tehozol, Erick Adrian Zamora , Loarce‐Martos, Jesus , Prieto‐González, Sergio , González, Raquel , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Maurier, F. , Meyer, Alain, Nagy‐Vincze, Melinda , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Ravichandran, Naveen , Gupta, Latika , Agarwal, Vikas , Naveen, R , Lilleker, James B , Sen, Parikshit , Joshi, Mrudula , Agarwal, Vishwesh , Kardes, Sinan , Day, Jessica , Makol, Ashima , Milchert, Marcin , Gheita, Tamer , Salim, Babur , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Chatterjee, Tulika , Tan, Ai Lyn , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Knitza, Johannes , Kuwana, Masataka , Nune, Arvind , Cavagna, Lorenzo , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Ziade, Nelly , Pauling, John D , Zamora Tehozol, Erick Adrian , De Angelis, Rossella , Singh, Yogesh Preet , Makol, Ashima , Gracia‐Ramos, Abraham Edgar , Chatterjee, Tulika , Shinjo, Samuel Katsuyuki , Nune, Arvind , Distler, Oliver , Aggarwal, Rohit , Group, the COVAD Study, Barman, Bhupen , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Cansu, Döndü Üsküdar , Wincup, Chris , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Gonzalez, Raquel Aranega, Yoshida, Akira , Gromova, Margarita Aleksandrovna , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena

Mayo Clinic

Rheumatology | May 25, 2023 | Volume: 63 | Issue: 3 | Pages: 657-664

10.1093/rheumatology/kead250 | PMID 37228012 Get It

Abstract Objectives We aimed to explore current practice and interregional differences in the treatment of idiopathic inflammatory myopathies (IIMs). We triangulated these observations considering countries' gross national income (GNI), disease subtypes, and symptoms using patient-reported information. Methods A cross-sectional ancillary analysis of the ‘COVID-19 vaccination in auto-immune disease’ (COVAD) e-survey containing demographic characteristics, IIM subtypes (DM, PM, IBM, anti-synthetase syndrome [ASSD], immune-mediated necrotizing myopathy [IMNM], overlap myopathies [OM]), current symptoms (surrogate for organ involvement) and treatments (corticosteroids [CS], immunomodulators [IM], i.e. antimalarials, immunosuppressants [IS], IVIG, biologic treatments and targeted-synthetic small molecules). Treatments were presented descriptively according to continents, GNI, IIM and organ involvement, and associated factors were analysed using multivariable binary logistic regressions. Results Of 18 851 respondents from 94 countries, 1418 with IIM were analysed (age 61 years, 62.5% females). DM (32.4%), IBM (24.5%) and OM (15.8%) were the most common subtypes. Treatment categories included IS (49.4%), CS (38.5%), IM (13.8%) and IVIG (9.4%). Notably, treatments varied across regions, GNI categories (IS mostly used in higher-middle income, IM in lower-middle income, IVIG and biologics largely limited to high-income countries), IIM subtypes (IS and CS associated with ASSD, IM with OM and DM, IVIG with IMNM, and biologic treatments with OM and ASSD) and disease manifestations (IS and CS with dyspnoea). Most inter-regional treatment disparities persisted after multivariable analysis. Conclusion We identified marked regional treatment disparities in a global cohort of IIM. These observations highlight the need for international consensus-driven management guidelines considering patient-centred care and available resources.
C66 PRIMARY RESULTS FROM APOLLO–B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN–MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
Longhi, Simone , Maurer, Mathew S. , Fontana, Marianna , Grogan, Martha , Gottlieb, Ronald H. , Yu, W. , Sekijima, Yoshiki , White, Matthew T. , Yureneva, Elena, Jay, Patrick Y. , Maurer, Mathew S , Fontana, Marianna , Berk, John L. , Gustafsson, Finn , Simões, M, Fernandes, Fábio Danziato , Gottlieb, R, Kubánek, Miloš , Poulsen, Steen Hvitfeldt , Damy, Thibaud , Diemberger, Igor , Tahara, Nobuhiro , Tang, W.H. Wilson , Obici, Laura , González-Duarte, Alejandra , Vest, J, Gillmore, Julian D.

Mayo Clinic

European Heart Journal Supplements | May 18, 2023 | Volume: 25 | Issue: Supplement_D | Pages: D28-D28

10.1093/eurheartjsupp/suad111.065 Get It

Abstract Introduction Transthyretin–mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Patisiran, an IV RNAi therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy. The safety and efficacy of patisiran in patients with wild–type or hereditary ATTR amyloidosis with cardiomyopathy (CM) is being investigated in the ongoing APOLLO–B study. Methods Patients were 18–85 yrs old with evidence of cardiac amyloidosis by echocardiography, and ATTR amyloid by tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with CM. Medical history of heart failure (HF) due to ATTR amyloidosis with ≥1 prior hospitalization or current clinical evidence of HF was required. Patients were randomized 1:1 to patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. The primary endpoint was change from baseline in 6–MWT at Month 12 (M12) with patisiran vs placebo. Results APOLLO–B enrolled 360 patients (patisiran, n=181; placebo, n=179): median age (range), 76.0 (41, 85) yrs; male, 89%; wtATTR, 80%. Baseline characteristics were consistent between patients on tafamidis at baseline (91/360 [25%]) and those who were not. Patisiran achieved a rapid and sustained reduction in serum TTR, irrespective of baseline tafamidis treatment. At M12, patisiran showed a significant benefit vs placebo in 6–MWT (median [95% CI] change from baseline: patisiran, –8.15 [–16.42, 1.50]; placebo, –21.35 [–34.05, –7.52]; HL estimate of median difference: 14.69 [0.69, 28.69]; p=0.0162) and KCCQ–OS (LS mean [SEM] change from baseline: patisiran, 0.300 [1.263]; placebo, –3.408 [1.277]; LS mean [SEM] difference: 3.709 [1.796]; p=0.0397). Consistent benefits with patisiran in 6–MWT and KCCQ–OS were observed across predefined patient subgroups. Time to first event of all–cause hospitalization, urgent HF visit, or death directionally favored patisiran vs placebo (HR [95% CI], 0.839 [0.557, 1.263]), as did all–cause mortality (HR [95% CI], 0.355 [0.110, 1.138]), but all composite outcomes endpoints did not achieve statistical significance over 12 months. Patisiran was well tolerated; most AEs were mild or moderate in severity, and there were no cardiac safety concerns. Conclusions Benefits at 12 months were observed with patisiran vs placebo in functional capacity, and health status and quality of life, in patients with ATTR amyloidosis with CM. The efficacy and safety of patisiran continues to be studied in the APOLLO–B open–label extension.
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Tome, Maite , Abraham, Roselle, Balaji, Seshadri , Barth, Cheryl , Berul, Charles I. , Bos, Martijn, Cannom, David S. , Choudhury, Lubna , Concannon, Maryann, Cooper, Robert , Czosek, Richard J. , Dubin, Anne M. , Dziura, James, Eidem, Benjamin W., Etheridge, Susan P. , Geske, Jeffrey B. , Gray, Belinda , Lal, Ashwin K. , Ommen, Steven R., Saarel, Elizabeth V. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Day, Sharlene M. , Abrahms, Dominic Jr, Ashley, Euan A. , Aziz, Peter F. , Batra, Anjan S. , Ferhaan, Ahmad, Gollob, Michael J., Kanter, Ronald J. , Li, Walter, Masri, Ahmad , Murphy, Ann Mooney, Popjes, Eric , Rao, Roopa S, Rosenthal, David N. , Semsarian, Chris, Shah, Maully J. , Tardif, Jill, Towbin, Jeffrey A. , Turer, Aslan T., Bos, J. Martijn , Eidem, Benjamin, Bos, Johan M , Dubin, Anne M , Ware, James S , Geske, Jeffrey B , Tome Esteban, Maria Teresa , Gray, Belinda , Salberg, Lisa , Ho, Carolyn Y. , Dziura, James, Emery, Michael S. , Estes, N.A. Mark , Hall, Kevin D. , Harmon, Kimberly G. , James, Cynthia A. , Law, Ian H. , Li, Fangyong , Link, Mark S. , McKenna, William J. , Molossi, Silvana M , Olshansky, Brian , Saberi, Sara , Zipes, Douglas P. , Cerrone, Marina , Colan, Steven D. , Erickson, Christopher, Ferhaan, Ahmad, Johnsrude, Christopher L. , Kannankeril, Prince J. , Murphy, Ann, Nandi, Deipanjan , Pérez, Marco , Perry, James C. , Rao, Roopa, Sanatani, Shubhayan , Skinner, Jonathan R. , Webster, Gregory , Wever‐Pinzon, Omar , Wong, Timothy C.

Mayo Clinic

JAMA Cardiology | May 17, 2023 | Volume: 8 | Issue: 6 | Pages: 595

10.1001/jamacardio.2023.1042 | PMID 37195701 Get It

Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. Objective To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity. Design, Setting, and Participants This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reported levels of physical activity: sedentary, moderate, or vigorous-intensity exercise. This was a multicenter, observational registry with recruitment at 42 high-volume HCM centers in the US and internationally; patients could also self-enroll through the central site. Individuals aged 8 to 60 years diagnosed with HCM or genotype positive without left ventricular hypertrophy (phenotype negative) without conditions precluding exercise were enrolled. Exposures Amount and intensity of physical activity. Main Outcomes and Measures The primary prespecified composite end point included death, resuscitated sudden cardiac arrest, arrhythmic syncope, and appropriate shock from an implantable cardioverter defibrillator. All outcome events were adjudicated by an events committee blinded to the patient’s exercise category. Results Among the 1660 total participants (mean [SD] age, 39 [15] years; 996 male [60%]), 252 (15%) were classified as sedentary, and 709 (43%) participated in moderate exercise. Among the 699 individuals (42%) who participated in vigorous-intensity exercise, 259 (37%) participated competitively. A total of 77 individuals (4.6%) reached the composite end point. These individuals included 44 (4.6%) of those classified as nonvigorous and 33 (4.7%) of those classified as vigorous, with corresponding rates of 15.3 and 15.9 per 1000 person-years, respectively. In multivariate Cox regression analysis of the primary composite end point, individuals engaging in vigorous exercise did not experience a higher rate of events compared with the nonvigorous group with an adjusted hazard ratio of 1.01. The upper 95% 1-sided confidence level was 1.48, which was below the prespecified boundary of 1.5 for noninferiority. Conclusions and Relevance Results of this cohort study suggest that among individuals with HCM or those who are genotype positive/phenotype negative and are treated in experienced centers, those exercising vigorously did not experience a higher rate of death or life-threatening arrhythmias than those exercising moderately or those who were sedentary. These data may inform discussion between the patient and their expert clinician around exercise participation.
Guidelines for reasonable and appropriate care in the emergency department 3 ( GRACE ‐3): Acute dizziness and vertigo in the emergency department
Edlow, Jonathan A. , Carpenter, Christopher R. , Akhter, Murtaza , Khoujah, Danya , Marcolini, Evie G. , Meurer, William J. , Morrill, David, Naples, James G. , Ohle, Robert , Omron, Rodney , Sharif, Sameer , Siket, Matt , Upadhye, Suneel , Silva, Lucas Oliveira J. e , Sundberg, Etta, Tartt, Karen, Newman‐Toker, David E. , Carpenter, Christopher R , Marcolini, Evie , Oliveira J E Silva, Lucas , Vanni, Simone , Newman-Toker, David E , Bellolio, M Fernanda , Khoujah, Danya , Bellolio, Fernanda

Mayo Clinic

Academic Emergency Medicine | May 11, 2023 | Volume: 30 | Issue: 5 | Pages: 442-486

10.1111/acem.14728 | PMID 37166022 Get It

Abstract This third Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐3) from the Society for Academic Emergency Medicine is on the topic adult patients with acute dizziness and vertigo in the emergency department (ED). A multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding five questions for adult ED patients with acute dizziness of less than 2 weeks' duration. The intended population is adults presenting to the ED with acute dizziness or vertigo. The panel derived 15 evidence‐based recommendations based on the timing and triggers of the dizziness but recognizes that alternative diagnostic approaches exist, such as the STANDING protocol and nystagmus examination in combination with gait unsteadiness or the presence of vascular risk factors. As an overarching recommendation, (1) emergency clinicians should receive training in bedside physical examination techniques for patients with the acute vestibular syndrome (AVS; HINTS) and the diagnostic and therapeutic maneuvers for benign paroxysmal positional vertigo (BPPV; Dix–Hallpike test and Epley maneuver). To help distinguish central from peripheral causes in patients with the AVS, we recommend: (2) use HINTS (for clinicians trained in its use) in patients with nystagmus, (3) use finger rub to further aid in excluding stroke in patients with nystagmus, (4) use severity of gait unsteadiness in patients without nystagmus, (5) do not use brain computed tomography (CT), (6) do not use routine magnetic resonance imaging (MRI) as a first‐line test if a clinician trained in HINTS is available, and (7) use MRI as a confirmatory test in patients with central or equivocal HINTS examinations. In patients with the spontaneous episodic vestibular syndrome: (8) search for symptoms or signs of cerebral ischemia, (9) do not use CT, and (10) use CT angiography or MRI angiography if there is concern for transient ischemic attack. In patients with the triggered (positional) episodic vestibular syndrome, (11) use the Dix–Hallpike test to diagnose posterior canal BPPV (pc‐BPPV), (12) do not use CT, and (13) do not use MRI routinely, unless atypical clinical features are present. In patients diagnosed with vestibular neuritis, (14) consider short‐term steroids as a treatment option. In patients diagnosed with pc‐BPPV, (15) treat with the Epley maneuver. It is clear that as of 2023, when applied in routine practice by emergency clinicians without special training, HINTS testing is inaccurate, partly due to use in the wrong patients and partly due to issues with its interpretation. Most emergency physicians have not received training in use of HINTS. As such, it is not standard of care, either in the legal sense of that term (“what the average physician would do in similar circumstances”) or in the common parlance sense (“the standard action typically used by physicians in routine practice”).
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
Naveen, R, Sen, Parikshit , Griger, Zoltán , Day, Jessica , Joshi, Mrudula , Nune, Arvind , Nikiphorou, Elena , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Jagtap, Kshitij , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Lini, Daniele , Screiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Giollo, Alessandro, Alluno, Alessia, Ioannone, Florenzo, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Ravichandran, Naveen , Giollo, Alessandro , Schreiber, Karen , Gupta, Latika , Naveen, R , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Chen, Yi-Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Milchert, Marcin , Joshi, Mrudula , Day, Jessica , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Nune, Arvind , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Saha, Sreoshy , Griger, Zoltan , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Gracia‐Ramos, Abraham Edgar , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Barman, Bhupen , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira , Kimura, Naoki, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Emorinken, Airenakho , Ugarte‐Gil, Manuel F. , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | April 21, 2023 | Volume: 63 | Issue: 1 | Pages: 127-139

10.1093/rheumatology/kead180 | PMID 37084267 Get It

Abstract Objectives Disease flares in the post–coronavirus disease 2019 (COVID-19) vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022, respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history and vaccination details. Flares of IIMs were defined as (a) patient self-reported, (b) immunosuppression (IS) denoted, (c) clinical sign directed and (d) with >7.9-point minimal clinically significant improvement difference worsening of Patient-Reported Outcomes Measurement Information System (PROMIS) PROMISPF10a score. Risk factors of flares were analysed using regression models. Results Of 15 165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians) and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7% and 19.6% patients by definitions (a) to (d), respectively, with a median time to flare of 71.5 (10.7–235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR 1.2; 95% CI 1.03, 1.6, P = 0.025) were prone to flares, while those receiving rituximab (OR 0.3; 95% CI 0.1, 0.7, P = 0.010) and AZA (OR 0.3, 95% CI 0.1, 0.8, P = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in IS. Asthma (OR 1.62; 95% CI 1.05, 2.50, P = 0.028) and higher pain visual analogue score (OR 1.19; 95% CI 1.11, 1.27, P < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion A diagnosis of IIMs confers an equal risk of flares in the post–COVID-19 vaccination period to AIRDs, with active disease, female gender and comorbidities conferring a higher risk. Disparity between patient- and physician-reported outcomes represents a future avenue for exploration.
Abstract 4082: Impact of immunosuppressive monocytes on CART19 cell effector functions and outcomes
Yun, Kun , Huynh, Truc , Manriquez-Roman, Claudia, Sirpilla, Olivia , Stewart, Carli M. , Girsch, James H. , Ogbodo, Ekene J. , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Mattie, Mike , Nguyen-Mau, Sao-Mai, Sakemura, Reona , Cox, Michelle J. , Stewart, Carli , Can, İsmail , Kimball, Brooke , Hefazi, Mehrdad , Siegler, Elizabeth L. , Filosto, Simone , Kenderian, Saad S.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 4082-4082

10.1158/1538-7445.am2023-4082 Get It

Abstract CD19 directed chimeric antigen receptor T (CART19) cell therapy has resulted in remarkable outcomes in B cell malignancies and was FDA approved in multiple indications. However, durable remissions are limited to 40% of treated patients. Inhibitory myeloid cells in tumor microenvironment have been found to suppress T cell expansion and contribute to failure of CART19 cell therapy. In this study, we aimed to unravel the interactions between monocytes, CART19 cells and tumor cells to understand how monocytes-CART19 cell interactions impact CART19 cell effector functions and clinical outcomes. Two sets of experiments were conducted, 1) use of healthy CART19 cells, CD19+ tumor cells, and healthy monocytes; 2) use of brexu-cel products from ZUMA-2 clinical trial treating mantle cell lymphoma (MCL), patient-matched monocytes and circulating MCL tumor cells (n = 11; 6 durable responders, 2 relapsed after initial response and 3 non-responders). CD28 costimulated CART19 (CART19-28ζ) cells generated in the lab from healthy donors were co-cultured with donor freshly isolated monocytes in the presence of Jeko-1 cells (a CD19+ MCL cell line). CART19 antigen specific proliferation was not inhibited by freshly isolated monocytes. When monocytes were co-cultured with CART19 and tumor cells, higher levels of eotaxin, GRO, MCP-3 and IL-7 were detected. When CART19 cells were co-cultured with the CD19+ JeKo-1 cells in the presence of ex vivo M2 polarized macrophages, CART19 antigen specific proliferation was inhibited (p=0.0045). Transwell experiments demonstrate that M2-induced CART19 inhibition is not contact dependent. Cytokine profile analysis indicated increased level of IL-1ra, IP-10 and MCP-1 and decreased level of IL-17A, sCD40L, IL-9 and MIP-1α when M2 macrophages were co-cultured with CART19 and tumor cells compared to co-cultures of tumor cells and CART19. Then we conducted ex vivo co-cultures of brexu-cel products, autologous monocytes and circulating MCL tumor cells from MCL patients (ZUMA-2) collected prior to CART19 cell infusion. Here we observed trends of elevation of IL-13 and IL-5 and reduction of GRO, MCP-3, MIP-1β and IL-8 in non-responders, compared to responders (durable responses or relapsed patients). Our results support that monocyte- and macrophage-dependent cytokine release could modulate CART19 effector and trafficking functions, and thus CART19 clinical outcomes. This warrants further investigation around strategies to improve durable responses to CART cell therapy. Citation Format: Kun Yun, Reona Leo Sakemura, Michelle J. Cox, Truc Huynh, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, James H. Girsch, Ekene J. Ogbodo, Ismail Can, Brooke Kimball, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Elizabeth L. Siegler, Mike Mattie, Sao-Mai Nguyen-Mau, Simone Filosto, Saad S. Kenderian. Impact of immunosuppressive monocytes on CART19 cell effector functions and outcomes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4082.